2[1]Greiner MA,Lipshultz SE:Epidermiology of Anthracycline Cardiotoxicity in Children and Adults.Semin Oncol,1998,25:72.
3[2]Keefe DL:Anthracycline-Induced Cardiomyopathy.Semin in Oncol,2001,28 (4):2.
4[3]Safra T,Muggia F,Jeffers S,et al:Pegylated Liposomal Doxorubicin (Doxil):Reduced Clinical Cardiotoxicity in Patients Reaching or Exceeding Cumulative Doses of 500 mg/m2.Ann Oncol,2000,11:1029.
5[4]Safra T:Cardiac Safty of Liposomal Anthracyclines.The Oncologist,2003,8 (suppl 2):17.
6[5]Theodoulou M,Hudis C:Cardiac Profiles of Liposomal Anticlines:Great Cardiac Safty versus Conventional Doxorubicin? Cancer,2004,15:100 (10):2052.
7[6]Lipshultz SE,Rifai N,Dalton VM,et al:The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia.N Engl J Med,2004,351 (2):145.
9Gray c c,Amrani M,Yacoub M H,et al.Heast stress proteins and myocardial pritection:experiental motel or potential clinical tool[J].Int J Bioche Cell,1999;31(5):559.
10Hall TJ.Role of hsp70 in cytokine production[J].Experien-tia,1994;50(11-12):1048.
